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Results: The phantom study showed that phantom position 
was linearly correlated with the exit detector measurements 
resulting in an r > 0.99. The standard deviation in the 
measured breast surface position, σ, was 2.28 mm for the 
453 analyzed detector fluences (σmin = 1.39 mm, σmax = 
4.33 mm). The uncertainty in the detector measurements 
was estimated to be under one detector channel’s width. 
 
Conclusion: The σ results of this study should be an indicator 
of the overall positioning uncertainty in our IGRT process for 
these treatments, i.e. kVCT-MVCT image registration, patient 
movement, and respiratory motion. Even if only one 
projection of the treatment data was used in the estimation, 
our results compare very well with similar studies’ (von 
Tienhoven et al (1991), Smith et al (2005), Wang et al (2013)) 
findings on breast displacement due to respiratory motion. 
Furthermore, the novelty of this study is its evaluation of the 
breast position was performed on exit detector fluence of 
intensity-modulated fields, which we believe to be a first. 
 
OC-0361  
Simulation of clinical relevance errors detected by real-
time EPID-based patient verification system 
T. Fuangrod1, J. Simpson
1University of Newcastle, School of Electrical Engineering 
and Computer Science, Newcastle- NSW, Australia 
2,3, R. Middleton1, P. Greer2,3 
2Calvary Mater Newcastle, Radiation Oncology, Newcastle- 
NSW, Australia 
3University of Newcastle, School of Mathematical and 
Physical Sciences, Newcastle- NSW, Australia 
 
Purpose or Objective: A a real-time patient treatment 
verification system using EPID (Watchdog) for clinical 
implementation was developed as an advanced patient safety 
tool. However to use Watchdog for treatment intervention 
we need to understand its response to clinically significant 
errors. The purpose of this study is to investigate the 
performance of Watchdog under controlled error conditions.  
 
Material and Methods: The real-time verification system 
(Watchdog) utilises a comprehensive physics-based model to 
generate a series of predicted transit cine EPID image as a 
reference data set, and compares these to measured cine-
EPID images acquired during treatment. The agreement 
between the predicted and measured transit images is 
quantified using chi-comparison on a cumulative frame basis.  
To determine the ability of Watchdog to detect clinically 
significant errors during treatment delivery we used real 
patient data and simulated dosimetric and patient positional 
errors. Four study cases were used; dosimetric error in 
Prostate IMRT, HN patient weight loss, prostate displacement 
and lung SBRT displacement errors. These errors were 
introduced by modifying the planning CT scan data and re-
calculating the predicted EPID data set. The error embedded 
predicted EPID data sets were compared to the measured 
EPID data acquired during patient treatment.  
 
Results: The average % cumulative chi pass-rate across four 
case studies were 84.0% and 94.5% for 3%, 3mm and 4%, 4mm 
respectively. In the figures, the cumulative chi pass-rate 
results based on error simulation are shown. The difference 
ratio of chi comparison criteria between 3%, 3mm and 4%, 
4mm was approximately 13%. As a result, the threshold level 
should determine based on the criteria and clinical acceptant 
limit. 
 
 
Conclusion: We have evaluated our proposed real-time EPID-
based treatment verification system using clinical relevant 
error simulation in prostate, HN and lung cases. Using either 
a 3%, 3mm or 4%, 4mm criteria, the real-time EPID-based 
patient verification system successfully detected simulated 
errors introduced into patient plan deliveries; including 5% 
dosimetric errors on prostate IMRT, 5mm prostate IMRT 
displacement, 5% HN patient weight loss, and 5mm Lung SBRT 
displacement.  
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Purpose or Objective: The increasing complexity of modern 
radiation therapy requires major quality control (QC) to 
ensure safety and reliability of patients’ treatments. The 
large number of QCs requires a considerable amount of work 
that sometime is responsible of missing controls that may 
lead to dosimetric errors. In this frame the in vivo dosimetry 
(IVD) by EPID images has an important role to detect eventual 
dosimetric discrepancies between planned and delivered 
doses. The present work reports the results of 7500 IVD tests 
obtained in the last 2 years in 7 Italian Centers. 
 
Material and Methods: SOFTDISO is an IVD-program 
distributed by the Best Medical Italy for 3D-CRT ,IMRT and 
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VMAT treatments, and it is based on correlation functions 
between EPID signals and doses in patient. The software is 
easy to implement for Varian, Elekta and Siemens linacs, and 
it is connected with the Record and Verify system of the 
Center, supplying the results in a few seconds. The method 
supplies two tests (i) the ratio R=(Diso/Diso,TPS) between the 
reconstructed and computed isocentre dose, with pass 
criteria of ±5% and (ii) a 2D γ-analysis between EPID images 
with the following pass criteria: the percentage of the points 
Pγ<1 should be higher than 90% for 3DCRT and 95% for IMRT 
and VMAT; the γ-mean should be less than 0.5 and 0.3 for 
3DCRT and IMRT-VMAT respectively.  
 
Results: The percentage of the off-tolerance tests ranged 
between 10% and 17%, depending on the type of treatment 
checked. The causes of dosimetric discrepancies, in order of 
frequency were: setu-up variations, attenuators left in the 
field, morphological changes, TPS implementation and linac 
output factor. All the causes of the off-tolerance tests were 
justified and, once removed, the mean R values of all 
patients were within 5% and the γ-analysis indexes satisfied 
the specific pass criteria. The discrepancies due to patient 
morphological changes triggered new TC or CBCT scans to 
verify the need of an adaptive plane. Some of these cases 
have been discussed by radiotherapists and physicists. 
 
Conclusion: The multicenter result proved: (i) the great 
utility to obtain IVD tests in quasi real time, (ii) the positive 
role of the physicists during the dose-delivery step, (iii) 
SOFTDISO allows to understand the causes of dose 
discrepancies triggering adequate QC, and once the causes of 
errors were removed all the pass criteria were respected (iv) 
the role of IVD to intercept patient morphological changes to 
examine for eventual adaptive radiotherapy strategy. 
 
Proffered Papers: Physics 9: Adaptive RT for inter-fraction 
motion management  
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Purpose or Objective: To date no satisfactory treatment 
options exist for locally advanced lung cancer. Based on 
promising phase II studies, dose escalation gave hope for 
better local control. However, the phase III RTOG 0617 [1] 
dose escalation trial showed that treatment related deaths 
can increase. Strict normal tissue constraints, as well as 
focus on the actual delivered dose, are essential when aiming 
for safe dose escalation. For standard doses, adaptive 
radiotherapy (ART) has mainly been concerned with ensuring 
target coverage, but with escalated doses anatomical 
changes during treatment can result in critical over dosage of 
organs at risk (OARs). Furthermore, it is important to monitor 
doses to known OARs such as the heart, and other structures 
as connective tissue and chest wall, where we don’t know 
the risk for high dose RT. The present study investigates the 
impact of anatomical changes during RT on the escalated 
dose distribution used in the Danish NARLAL2 dose escalation 
trial. 
 
Material and Methods: Fifteen patients (pts) with a standard 
treatment plan and an experimental dose escalation plan 
were analysed. The standard plan delivered a homogeneous 
dose of 66 Gy/ 33 fractions (fx) while the experimental plan 
delivered a heterogeneous escalated dose distribution. The 
dose escalation was driven by the most FDG-PET active region 
of the tumour and lymph nodes, with mean doses up to 95 
Gy/ 33 fx and 74Gy/ 33 fx, respectively. The dose 
distribution was limited by constraints to the OARs (Table 1). 
All pts had a surveillance scan (sCT) at fx 10 and ten pts also 
at fx 20. The original treatment plans were recalculated on 
the sCTs to evaluate the impact of inter-fractional changes 
during the RT course. For most OARs, a maximum dose 
constraint was set, allowing higher doses for < 1cm3 of the 
OAR. The number of pts with OARs reaching the maximum 
dose for the escalation plan, was determined. For some pts, 
the volume receiving doses above the maximum constraint, 
increased on the sCT. Volume increments ΔV > 1cm3 were 
made up. 
 
 
 
Results: At least one OAR reached maximum dose constraint 
on planning CT (pCT) for all pts. Of these, 9 pts showed doses 
to OARs increasing above maximum dose on sCT, see Table. 
Heart doses (V50Gy) increased more than 1cm3 (up to 19 
cm3) in eight pts and in one pt the oesophagus was over 
dosed on the sCT. For connective tissue and chest wall, the 
volume receiving > 74 Gy increased more than 1cm3 on the 
sCT in 7 and 5 pts, respectively. The anatomical changes 
leading to higher OAR doses were tumour shrinkage (5 pt), 
body contour changes (3 pt) and resolving atelectasis (1 
pt).The mean dose to the PET-GTVT was 92±3Gy. In six pts, 
the mean dose decreased more than 1% (up to 10%) on the 
sCT. 
 
 
Conclusion: Anatomical changes during RT may result in 
increased doses to OAR. Introduction of dose escalation 
therefore requires frequent evaluation of treatment plans 
and ART should be used in order to avoid over dosage of 
OARs. 
